Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background — Chlamydia pneumoniae commonly causes respiratory infection, is vasotropic, causes atherosclerosis in animal models, and has been found in human atheromas. Whether it plays a causal role in clinical coronary artery disease (CAD) and is amenable to antibiotic therapy is uncertain. Methods and Results —CAD patients (n=302) who had a seropositive reaction to C pneumoniae (IgG titers ≥1:16) were randomized to receive placebo or azithromycin, 500 mg/d for 3 days, then 500 mg/wk for 3 months. Circulating markers of inflammation (C-reactive protein [CRP], interleukin [IL]-1, IL-6, and tumor necrosis factor [TNF]-α), C pneumoniae antibody titers, and cardiovascular events were assessed at 3 and 6 months. Treatment groups were balanced, with age averaging 64 (SD=10) years; 89% of the patients were male. Azithromycin reduced a global rank sum score of the 4 inflammatory markers at 6 (but not 3) months ( P =0.011) as well as the mean global rank sum change score: 531 (SD=201) for active drug and 587 (SD=190) for placebo ( P =0.027). Specifically, change-score ranks were significantly lower for CRP ( P =0.011) and IL-6 ( P =0.043). Antibody titers were unchanged, and number of clinical cardiovascular events at 6 months did not differ by therapy (9 for active drug, 7 for placebo). Azithromycin decreased infections requiring antibiotics (1 versus 12 at 3 months, P =0.002) but caused more mild, primarily gastrointestinal, adverse effects (36 versus 17, P =0.003). Conclusions —In CAD patients positive for C pneumoniae antibodies, global tests of 4 markers of inflammation improved at 6 months with azithromycin. However, unlike another smaller study, no differences in antibody titers and clinical events were observed. Longer-term and larger studies of antichlamydial therapy are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Heart Disease: A Textbook of Cardiovascular Medicine.
(1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-3-415_3 · Cited by 4,109
Saikku, P., Mattila, K., Nieminen, M. S., Huttunen, J. K., Leinonen, M., Ekman, M.-R., Mäkelä, P. H., & Valtonen, V (1988) · The Lancet · doi:10.1016/s0140-6736(88)90741-6 · Cited by 1,964
van der Wal, A. C., Becker, A. E., van der Loos, C. M., & Das, P. K. (1994) · Circulation · doi:10.1161/01.cir.89.1.36 · Cited by 1,910
Procedures for Comparing Samples with Multiple Endpoints
O'Brien, P. C. (1984) · Biometrics · doi:10.2307/2531158 · Cited by 1,162
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Cermak, J., Key, N., Bach, R., Balla, J., Jacob, H., & Vercellotti, G. (1993) · Blood · doi:10.1182/blood.v82.2.513.513 · Cited by 839
Saikku, P., Leinonen, M., Tenkanen, L., Linnanmäki, E., Ekman, M.-R., Manninen, V., Mänttäri, M., Frick, M. H., & Huttunen, J. K. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-4-273 · Cited by 786
Demonstration of Chlamydia pneumoniae in Atherosclerotic Lesions of Coronary Arteries
Kuo, C.-C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L., & Grayston, J. T. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.4.841 · Cited by 762
Shah, P. K., Falk, E., Badimón, J. J., Fernández‐Ortíz, A., Mailhac, A. C., Villareal-Levy, G., Fallon, J. T., Regnström, J., & Fuster, V. (1995) · PubMed · Cited by 722
Cited by
Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., et al. (2006) · Stroke · doi:10.1161/01.str.0000223048.70103.f1 · Cited by 1,368
Identification of Periodontal Pathogens in Atheromatous Plaques
Haraszthy, V. I., Zambon, J. J., Trevisan, M., Zeid, M., & Genco, R. J. (2000) · Journal of Periodontology · doi:10.1902/jop.2000.71.10.1554 · Cited by 1,120
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
Inflammation and Infections as Risk Factors for Ischemic Stroke
Lindsberg, P. J., & Grau, A. J. (2003) · Stroke · doi:10.1161/01.str.0000089015.51603.cc · Cited by 519
Black, P. H. (2003) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(03)00048-5 · Cited by 502
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Circulation · doi:10.1161/01.cir.103.1.163 · Cited by 373
Kerr, R., Stirling, D., & Ludlam, C. A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03061.x · Cited by 362
Anti-inflammatory effects of macrolide antibiotics
Čulić, O., Eraković, V., & Parnham, M. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01321-8 · Cited by 334
D'Aiuto, F., Parkar, M., Nibali, L., Suvan, J., Lessem, J., & Tonetti, M. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.018 · Cited by 332
“FMPSy 55 F 20 (50-69) 9 F 15T (7-21) 11 F 12T (10-21) b.”
InfluentialMayr, M., Kiechl, S., Willeit, J., Wick, G., & Xu, Q. (2000) · Circulation · doi:10.1161/01.cir.102.8.833 · Cited by 297
<EMPH TYPE="ITAL">Chlamydia pneumoniae</EMPH> as an Emerging Risk Factor in Cardiovascular Disease
Kalayoglu, M. V. (2002) · JAMA · doi:10.1001/jama.288.21.2724 · Cited by 283
Background and Current Knowledge of Chlamydia pneumoniae and Atherosclerosis
Grayston, J. T. (2000) · The Journal of Infectious Diseases · doi:10.1086/315596 · Cited by 281
Periodontal disease and C‐reactive protein‐associated cardiovascular risk
D'Aiuto, F., Ready, D., & Tonetti, M. S. (2004) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2004.00731.x · Cited by 279
Gorelick, P. B. (2002) · Stroke · doi:10.1161/hs0302.103657 · Cited by 210
Muhlestein, J. B., Anderson, J. L., Carlquist, J. F., Salunkhe, K., Horne, B. D., Pearson, R. R., Bunch, T. J., Allen, A., Trehan, S., & Nielson, C. (2000) · Circulation · doi:10.1161/01.cir.102.15.1755 · Cited by 207
Self-citationChlamydia pneumoniae and atherosclerosis
Belland, R. J., Ouellette, S. P., Gieffers, J., & Byrne, G. I. (2004) · Cellular Microbiology · doi:10.1046/j.1462-5822.2003.00352.x · Cited by 199
“The designs of these trials were not perfect (Grayston, 1998; Anderson et al., 1999), and the studies recruited too few patients to detect moderate differences after treatment.”
BackgroundInfectious Agents Are Not Necessary for Murine Atherogenesis
Wright, S. D., Burton, C., Hernandez, M., Hassing, H., Montenegro, J., Mundt, S., Patel, S., Card, D. J., Hermanowski-Vosatka, A., Bergstrom, J. D., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.8.1437 · Cited by 176
Macrolide Antibiotics and the Risk of Cardiac Arrhythmias
Albert, R. K., & Schuller, J. L. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201402-0385ci · Cited by 163
Metadata
- Authors
- Anderson, J. L., Muhlestein, J. B., Carlquist, J., Allen, A., Trehan, S., Nielson, C., Hall, S., Brady, J., Egger, M., Horne, B., & Lim, T.
- Venue
- Circulation
- Published
- 1999-03-30
- Volume
- 99
- Issue
- 12
- Pages
- 1540-1547
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993298922
- Cited by
- 335
- References
- 34
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.